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INTRODUCTION
Brazilian spotted fever (BSF), an acute febrile
rickettsiosis, transmitted more frequently by the
ixodid tick Amblyomma cajennense and caused by
Rickettsia rickettsii, is the most important tick-
borne disease (TBD) in Brazil [1]. First described
in 1929, in the state of Sa˜o Paulo (SP), it became an
important public heath problem only after the
1980s, due to an increasing number of cases and a
high case–fatality ratio mostly in southeastern
Brazil [1]. It was only in 2001 that BSF became the
ﬁrst (and only) noticeable TBD in Brazil. Usually
associated with a severe clinical picture, even
among early-treated patients, with haemorrhagic
manifestations and multi-organ dysfunction [1],
BSF ﬁgures as one the most important life-threat-
ening transmissible diseases in Brazil. In 2003,
when the ﬁrst BSF conﬁrmed cases were identi-
ﬁed in the state of Santa Catarina (SC), an unusual
benign evolution was observed there [2].
We describe and compare the clinical charac-
teristics and evolution of BSF in two different
states of Brazil.
PATIENTS AND METHODS
Retrospective case-series study of the clinical aspects of
conﬁrmed BSF cases of two Brazilian states (Sao Paulo in the
southeast and Santa Catarina in the south) from 2003 to 2006
was carried out. Data were obtained from the National
Information System of the Brazilian Health Ministry. All cases
were conﬁrmed by laboratory criteria that included fourfold
rise in two serum samples by indirect immunoﬂuorescence
assay, R. rickettsii isolation in culture cell (from skin or blood
clot specimens), or immunohistochemistry of ﬁxed tissues. For
the SC cases, only indirect immunoﬂuorescence assay was
available. All testings were performed at the same public
health reference laboratory.
RESULTS
Two case-series with 126 conﬁrmed cases from SP
and 61 from SC were compared. The frequency of
clinical signs and symptoms is shown in Table 1.
There was no signiﬁcant statistical difference
between the two groups for clinical manifesta-
tions such as fever, myalgia, abdominal pain,
diarrhoea, vomiting, prostration and conjunctival
hyperaemia. The frequency of exanthema was less
than 50% in both series and icterus was present in
both series. Despite the higher frequency of
headache in SC (90% vs. 69%), no patient pre-
sented with neurological complications. In SC
lymphadenopathy is an important clinical sign
and occurs in 49% of the patients whereas in SP it
occurred in only 4% of the patients. Clinical
manifestations usually associated with a more
severe disease (haemorrhagic phenomena, respi-
ratory distress, hypotension, shock, and gan-
grene) were more frequent in SP. This ﬁnding
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supports the most signiﬁcant difference between
the two compared case-series: the case–fatality
ratio in SP varied from 26% to 40% during the
study period; in SC no deaths occurred.
DISCUSSION
Since 1929, BSF has been described as a life-
threatening disease, usually associated with
haemorrhagic manifestations and multi-organ
dysfunction [1]. In Brazil, where BSF transmission
is observed in 9 of the 27 federative units,
especially in the southeastern and southern
regions, the lethality varied from 24% in the state
of Minas Gerais to 36% in SP [2]. Because of
elevated frequency of haemorrhage, icterus, neu-
rological changes and respiratory distress, and
high lethality, BSF seems more severe than Rocky
Mountain spotted fever (RMSF), despite the shar-
ing of the same aetiological agent [1].
As we demonstrate in this comparative study,
BSF in the state of SC is an exception that must be
better understood. The clinical picture of BSF in
SC, as a mild disease, with lymphadenopathy and
no severe or fatal cases, suggests that the infecting
agent could be a Rickettsia other than R. rickettsii.
Recently in Brazil, the ﬁrst cases of human
Rickettsia felis infections, diagnosed by serological
assays, were described presenting as a mild
disease [3]. Recognised as a human pathogen in
2004 [4], Rickettsia parkeri was found to be infect-
ing ticks from Uruguay (2004) and Brazil (2007)
[5]. It caused a less severe disease when compared
with other spotted fevers, like BSF and RMSF [4],
with some clinical aspects, including lymphade-
nopathy and favourable prognosis, that resemble
the disease described in SC. Because of the cross-
reactivity among spotted fever group Rickettsiae
and of the common use of only R. rickettsii
antigens for serological diagnosis of BSF [4,5], it
is possible that a less virulent strain of R. rickettsii
or of other unidentiﬁed spotted fever group
Rickettsiae than R. rickettsii, including R. parkeri
and potentially pathogenic species like R. am-
blyommii [4], could be the aetiological agent of the
spotted fever observed in SC and described here.
Thus, efforts should be made to detect the agent
in human cases using techniques of isolation and
molecular characterisation.
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Table 1. Frequency of signs and symptoms of BSF cases in
the states of Sa˜o Paulo and Santa Catarina, Brazil, 2003–
2006
Clinical ﬁndings
Frequency of signs and symptoms
p value
Sa˜o Paulo
(n = 126)
Santa
Catarina (n = 61)
Fever 88.9% (112) 95.1% (58) 0.16
Headache 69% (87) 90.2% (55) <0.01
Myalgia 65.9% (83) 80.3% (49) 0.04
Exanthem 34.9% (44) 49.2% (30) 0.06
Prostration 57.9% (73) 57.4% (35) 0.9
Abdominal pain 39.7% (50) 36.1% (22) 0.6
Nausea ⁄vomiting 31.7% (40) 39.3% (24) 0.3
Diarrhoea 17.5% (22) 14.8% (9) 0.6
Conjunctival hyperaemia 21.4% (27) 18% (11) 0.5
Petechiae 36.5% (46) 8.2% (5) <0.01
Haemorrhage 26.2% (33) 1.6% (1) <0.01
Hypotension ⁄ shock 23.8% (30) 3.3% (2) <0.01
Coma 19% (24) 0 <0.01
Respiratory distress 17.5% (22) 6.6% (4) 0.02
Icterus 16.7% (21) 9.8% (6) <0.01
Convulsion 14.3% (18) 0 <0.01
Renal failure 103% (13) 8.2% (5) 0.6
Hepato and splenomegaly 8.7% (11) 0 0.01
Adenomegaly 4% (5) 49.2% (30) <0.01
Gangrene 3.2% (4) 0 0.1
Lethality (mean) 36.8 (26.2–40) 0 <0.01
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